Yeni bir biyolojik belirteç olarak C-reaktif protein

Translated title of the contribution: C-reactive protein as a novel biomarker

Nader Elgharib, David S. Chi, Walid Younis, Salim Wehbe, Guha Krishnaswamy

Research output: Contribution to journalArticle

Abstract

CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.

Original languageUndefined/Unknown
Pages (from-to)33-38
Number of pages6
JournalSENDROM
Volume16
Issue number12
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

C-Reactive Protein
Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Exercise Test
Cardiovascular Diseases
Guidelines
Therapeutics
oxidized low density lipoprotein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Elgharib, N., Chi, D. S., Younis, W., Wehbe, S., & Krishnaswamy, G. (2004). Yeni bir biyolojik belirteç olarak C-reaktif protein. SENDROM, 16(12), 33-38.

Yeni bir biyolojik belirteç olarak C-reaktif protein. / Elgharib, Nader; Chi, David S.; Younis, Walid; Wehbe, Salim; Krishnaswamy, Guha.

In: SENDROM, Vol. 16, No. 12, 12.2004, p. 33-38.

Research output: Contribution to journalArticle

Elgharib, N, Chi, DS, Younis, W, Wehbe, S & Krishnaswamy, G 2004, 'Yeni bir biyolojik belirteç olarak C-reaktif protein', SENDROM, vol. 16, no. 12, pp. 33-38.
Elgharib N, Chi DS, Younis W, Wehbe S, Krishnaswamy G. Yeni bir biyolojik belirteç olarak C-reaktif protein. SENDROM. 2004 Dec;16(12):33-38.
Elgharib, Nader ; Chi, David S. ; Younis, Walid ; Wehbe, Salim ; Krishnaswamy, Guha. / Yeni bir biyolojik belirteç olarak C-reaktif protein. In: SENDROM. 2004 ; Vol. 16, No. 12. pp. 33-38.
@article{49d9501edc7f4eec961d6782cc0b9375,
title = "Yeni bir biyolojik belirte{\cc} olarak C-reaktif protein",
abstract = "CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.",
author = "Nader Elgharib and Chi, {David S.} and Walid Younis and Salim Wehbe and Guha Krishnaswamy",
year = "2004",
month = "12",
language = "Undefined/Unknown",
volume = "16",
pages = "33--38",
journal = "SENDROM",
issn = "1016-5134",
publisher = "Turkish Anaesthesiology and Intensive Care Society",
number = "12",

}

TY - JOUR

T1 - Yeni bir biyolojik belirteç olarak C-reaktif protein

AU - Elgharib, Nader

AU - Chi, David S.

AU - Younis, Walid

AU - Wehbe, Salim

AU - Krishnaswamy, Guha

PY - 2004/12

Y1 - 2004/12

N2 - CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.

AB - CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.

UR - http://www.scopus.com/inward/record.url?scp=11844262716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844262716&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:11844262716

VL - 16

SP - 33

EP - 38

JO - SENDROM

JF - SENDROM

SN - 1016-5134

IS - 12

ER -